Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,743 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 2 Interventional Results available

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

NCT05128162
View directory record Official record
Conditions
Fibromyalgia
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Kevin Boehnke
Other
Eligibility
25 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

NCT05903183
View directory record Official record
Conditions
Healthy
Interventions
IVX-A12, Placebo
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2010 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control

NCT03528369
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
CGS-200-1, CGS-200-5, CGS-200 Vehicle
Drug
Lead sponsor
Propella Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 3 Interventional Results available

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

NCT00317642
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation), placebo, cytarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
55 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

18750-Sun Protection Factor Assay

NCT02741466
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Coppertone (BAY987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

NCT00761722
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Leukemia, Myelomonocytic, Chronic
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
11
States / cities
Greenbrae, California • Ocoee, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00927472
View directory record Official record
Conditions
Pediculosis
Interventions
Malathion gel 0.5%, Permethrin 1% rinse
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bentonville, Arkansas • Jonesboro, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 3, 2026, 5:17 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Recruiting Phase 2 Interventional

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445
View directory record Official record
Conditions
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
Drug · Other
Lead sponsor
ONL Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 3 Interventional Results available

A Study of Leuprolide to Treat Prostate Cancer

NCT00626431
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Nov 3, 2026, 5:17 AM EST
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Nov 3, 2026, 5:17 AM EST
Recruiting Phase 1 Interventional

Losartan + Sunitinib in Treatment of Osteosarcoma

NCT03900793
View directory record Official record
Conditions
Osteosarcoma
Interventions
Losartan, Sunitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

NCT03839693
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Pinellas Park, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone controlled-release test formulation, Immediate-release reference drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions

NCT00602134
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
6-Mercaptopurine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis

NCT01450709
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Kibow Biotics
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects

NCT00932763
View directory record Official record
Conditions
Healthy
Interventions
Amlodipine besylate, Norvasc
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 45 Years
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2009 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

NCT01487811
View directory record Official record
Conditions
Diabetes, Healthy
Interventions
biphasic insulin aspart 30
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Results available

A Case Formulation Approach to Cognitive Processing Therapy

NCT04407767
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Case Formulation plus Cognitive Processing Therapy, Cognitive Processing Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Honolulu, Hawaii • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2 Interventional

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393
View directory record Official record
Conditions
HIV Infections
Interventions
ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Nov 3, 2026, 5:17 AM EST